Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.61 |
| ▸ | VIPR2 | P41587 | 7/20 | 0.59 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.57 |
| ▸ | HRAS | P01112 | 1/20 | 0.53 |
| ▸ | KRAS | P01116 | 1/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30719468 | 0.95 | TFPI (0.60) | TFPIVIPR2VIPR1PTH1RHRAS | |
| SCHEMBL29407944 | 0.90 | VIPR2 (0.62) | TFPIVIPR2VIPR1HRASKRAS | |
| SCHEMBL29487598 | 0.89 | VIPR2 (0.62) | TFPIVIPR2VIPR1PTH1R | |
| SCHEMBL29487597 | 0.89 | VIPR2 (0.63) | TFPIVIPR2VIPR1PTH1R | |
| SCHEMBL31179921 | 0.87 | TFPI (0.67) | TFPIVIPR2VIPR1PTH1R | |
| SCHEMBL29572169 | 0.87 | MAPK8 (0.59) | TFPI | |
| SCHEMBL31005900 | 0.86 | BACE1 (0.59) | VIPR2VIPR1 | |
| SCHEMBL31182801 | 0.86 | VIPR2 (0.67) | TFPIVIPR2VIPR1PTH1RHRAS | |
| Skekigkefkrivqrikdflr SCHEMBL30338004 | 0.86 | PTH1R (0.64) | TFPIVIPR2VIPR1PTH1R | |
| SCHEMBL29694510 | 0.85 | VIPR2 (0.61) | TFPIVIPR2VIPR1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4133115-A1 | GENETICALLY REPROGRAMMED MYCOPLASMA BACTERIA AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2023-02-15 | — | — | EP | claimed |
| EP-4736894-A1 | ANTIMICROBIAL PEPTIDE-FUNCTIONALIZED CROSSLINKABLE COPOLYMER, CROSSLINKED COPOLYMER AND HYDROGEL WITH ANTIBACTERIAL ACTIVITY | Universität Siegen, Körperschaft des öffentlichen Rechts (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260027192-A1 | COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT | UNIV HONG KONG SCIENCE & TECH (CN) | 2026-01-29 | — | — | US | disclosed |
| CN-119707521-A | Formula and method for preparing foamed ceramic by dry powder preparation | 内蒙古建亨绿材科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250101062-A1 | ANTIMICROBIAL PEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2025-03-27 | — | — | US | disclosed |
| US-20240294572-A1 | Antimicrobial Peptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-05 | — | — | US | disclosed |
| WO-2024141791-A2 | COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-114621204-B | Pyrimidine-dione-acyl-containing poly-substituted piperazine derivative and preparation method and application thereof | 山东大学 | 2024-04-02 | — | — | CN | disclosed |
| US-11654259-B2 | Microcatheter | ORBUSNEICH MEDICAL (SHENZHEN) CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| CN-111892646-B | Antibacterial peptide derivative and application thereof in preparation of antibacterial infection medicines | 中国人民解放军军事科学院军事医学研究院 | 2023-05-02 | — | — | CN | disclosed |
| CN-111892646-B | Antibacterial peptide derivative and application thereof in preparation of antibacterial infection medicines | 中国人民解放军军事科学院军事医学研究院 | 2023-05-02 | — | — | CN | disclosed |
| EP-4133115-A1 | GENETICALLY REPROGRAMMED MYCOPLASMA BACTERIA AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022226297-A1 | ANTIMICROBIAL PEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-10-27 | — | — | WO | disclosed |
| US-11384380-B2 | Compositions and methods for detecting N6-methyladenine in the mammalian genome | YALE UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114621204-A | Pyrimidinedione-containing acyl polysubstituted piperazine derivative and preparation method and application thereof | 山东大学 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027192-A1 | COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT | IAPP, NPY1R, GLP1R | TFPI 2151/4885VIPR2 796/4885VIPR1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.